Observational study of monkeypox infection in Brazil

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study is a prospective cohort investigation that aims to evaluate clinical and immune-metabolic factors associated with the risk and severity of monkeypox infection in Brazil. It plans to enroll at least 80 patients over a six-month period, with follow-up assessments conducted through decentralized visits for 90 days post-inclusion. The study will utilize viral genomic analysis and untargeted metabolomics to gather data on the infection's impact.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women aged ≥ 18 years with confirmed MPOX infection.

(laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization)

Exclusion Criteria:

* Inability to provide informed consent;
* Patient who, judging by the study team, does not have a condition for decentralized follow-up

Where it's running

• Hospital Universitário João de Barros Barreto
  Belém, Pará, Brazil Recruiting
• Hospital Israelita Albert Einstein
  São Paulo, São Paulo, Brazil Recruiting
• Hospital Naval Marcílio Dias
  Rio de Janeiro, Brazil Recruiting

Study contacts

• Study coordinator: Henrique AR Fonseca, PhD
• Email: henrique.fonseca@einstein.br
• Phone: +5511968308958

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mpox sample collection with SDS-EDTA paper strips in DRC

  A study tests whether SDS-EDTA-treated chromatography paper strips can collect mpox samples as well as standard swabs for lab testing in people with suspected mpox in South Kivu, DRC.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Bukavu · NCT07634081

• Safety, tolerability, and how the body processes BSY001 after single and multiple doses

  This trial will test whether BSY001 is safe, well tolerated, and how it is absorbed and cleared when given once or multiple times to healthy adults aged 18–50.

  Recruiting Phase 1 China National Biotec Group Company Limited · Hangzhou · NCT07377175

• See if LC16m8 mpox vaccine protects people in the DRC

  This study tests whether the LC16m8 mpox vaccine helps prevent mpox in people aged 12 months and older in the DRC.

  Recruiting International Vaccine Institute · Kinshasa · NCT07093489

• Assessing immune responses to Mpox in outbreak regions

  This study is trying to see how people's immune systems respond to the Mpox virus in outbreak areas by collecting samples from those who may have been exposed, infected, or vaccinated.

  Recruiting University of Birmingham · Kigali · NCT06887556

• Evaluating the long-term effects of a booster dose of MVA-BN vaccine for monkeypox

  This study is testing how well a booster dose of the MVA-BN vaccine works over time in men over 18 who have already had two doses to help protect against monkeypox.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, Paris · NCT06885853

• Two-dose MVA monkeypox live vaccine in adults

  This trial will test whether two doses of an MVA-strain monkeypox live vaccine are safe and produce an immune response in adults, including healthy people, men who have sex with men, and people living with HIV.

  Recruiting Phase 1 Shanghai Institute Of Biological Products · Zhengzhou, Henan · NCT06771479

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.